The market is pricing the stock in line with historical averages, assuming steady-state growth.
Moderate quality score of 52/100, reflecting stable operating margins and manageable leverage.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: Average quality business weighed down by significant solvency concerns.
Wall Street is cautious, forecasting potential downside alongside robust expected earnings growth. This is paired with healthy capital returns, anchored by a strong, well-covered dividend yield.
CZNC demonstrates strong business quality with robust profitability and healthy margins. However, this is severely offset by a highly leveraged balance sheet (Debt/EBITDA > 4.0x) and elevated financial risk.
The company exhibits steady, low-single-digit revenue growth however, earnings have severely contracted over the same period. The company maintains healthy operational efficiency with a 20.4% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $39.6M | +0.3% | +0.3% | +3.3% | +6.4% | |
| EBITDA | $32.5M | — | -3.7% | — | — | |
| Net Income | $16.3M | -9.8% | -4.2% | — | +3.6% | |
| EPS (Diluted) | $0.92 | -13.6% | -5.1% | +2.5% | +0.8% | |
| Free Cash Flow | $18.0M | -3.3% | -1.3% | +6.8% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 79.8% | 97.4% | 96.3% | 97.2% |
| Operating Margin | 20.4% | 28.8% | 30.7% | 32.6% |
| Net Margin | 27.7% | 23.2% | 24.9% | 25.8% |
| FCF Margin | 41.3% | 29.2% | 29.9% | 30.0% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q4'26Latest | $0.68 | $0.92 | +35.3% | ||
| Q3'26 | $0.63 | $0.79 | +25.4% | ||
| Q2'26 | $0.58 | $0.02 | -96.6% | ||
| Q1'26 | $0.58 | $0.56 | -3.4% | ||
| Q4'25 | $0.53 | $0.47 | -11.3% | ||
| Q3'25 | $0.47 | $0.40 | -14.9% | ||
| Q2'25 | $0.44 | $0.41 | -6.8% | ||
| Q1'25 | $0.45 | $0.53 | +17.8% |
Total return is +46.1% (1Y), outperforming the benchmark by +35.4%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +42.6% | +35.7% | — |
| 1Y | +46.1% | +35.4% | +5.8% |
| 3YCAGR | +15.1% | -2.4% | +16.8% |
| 5YCAGR | +4.1% | -4.7% | +20.9% |
| 10YCAGR | +4.7% | -7.8% | — |
The S&P 500 is at 22.0x trailing P/E — Fair relative to historical averages.
Quick answers to common questions about Citizens & Northern Corporation (CZNC) valuation, health, and returns.
Based on peer relative multiples, Citizens & Northern Corporation appears Fair versus peers compared to industry peers.
Citizens & Northern Corporation has multiple valuation anchors: Peer Relative Fair Value: $27.69 | Wall Street Analyst Target: $23.50 (implying -14.0% upside). A convergence of these signals offers higher conviction.
Citizens & Northern Corporation displays fair financial health with a composite quality score of 52/100, supported by a Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 4.2%.
Citizens & Northern Corporation pays a 3.7% dividend yield, covered by a 70% payout ratio with 0 years of growth, supplemented by a 0.0% buyback yield.
Citizens & Northern Corporation's current growth trajectory is Stable. The company achieved +0.3% 1Y revenue growth and -13.6% 1Y EPS growth, compared to its 3Y revenue CAGR of +0.3%.
Wall Street consensus is Hold based on 1 analysts, beating EPS expectations in 33% of recent quarters with a 2-quarter streak. The consensus price target represents a -14.0% change from current levels.
Investment risks for Citizens & Northern Corporation include: -15.3% 1-year max drawdown. Volatility risk is characterized by a beta of 0.12x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.